Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levornidazole and sodium chloride injection for pelvic anaerobic bacterial infection
CTR20260915Phase 4Active
- Sponsor
- Shijiazhuang No. 4 Pharmaceutical
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of levornidazole in Pelvic anaerobic infection, acute endometritis, myometritis, Pelvic cellulitis, Tubo-ovarian abscess (TOA), sponsored by Shijiazhuang No. 4 Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
levornidazole
03
Conditions
Pelvic anaerobic infectionacute endometritismyometritisPelvic cellulitisTubo-ovarian abscess (TOA)
Beyond the preview
Go deeper on CTR20260915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260915.